Search company, investor...

Founded Year



Series B - II | Alive

Total Raised


Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+50 points in the past 30 days

About Bionaut Labs

Bionaut Labs operates as a precision biotechnology company. It designs and manufactures intra- tissue navigation using Bionaut nano, microrobots operating inside the body. It offers remote-controlled micro-robots revolutionizing the treatment of central nervous system (CNS) disorders targeting deep brain structures. Its devices cater to therapeutic, microsurgical, diagnostic, sensing, monitoring, and stimulatory issues. The company was founded in 2016 and is based in Los Angeles, California.

Headquarters Location

3767 Overland Avenue Suite 114

Los Angeles, California, 90034,

United States



Bionaut Labs's Product Videos

Bionaut Labs's Products & Differentiators

    Bionaut - Dandy Walker Malformation

    Device only application for Bionaut to treat a rare form of pediatric hydrocephalus, know as Dandy Walker Malformation


Expert Collections containing Bionaut Labs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bionaut Labs is included in 1 Expert Collection, including Digital Health.


Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Bionaut Labs Patents

Bionaut Labs has filed 16 patents.

The 3 most popular patent topics include:

  • medical equipment
  • surgical removal procedures
  • digestive system surgery
patents chart

Application Date

Grant Date


Related Topics



Surgical removal procedures, Surgery, Medical equipment, Surgical procedures and techniques, Orthopedic surgical procedures


Application Date


Grant Date


Related Topics

Surgical removal procedures, Surgery, Medical equipment, Surgical procedures and techniques, Orthopedic surgical procedures



Latest Bionaut Labs News

Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc.

Feb 21, 2024

Key Findings of the Market Report The market for oncolytic virus immunotherapy is growing due to rising awareness of cancer therapies in the wake of a growing number of people affected by the disease and the availability of innovative immuno-oncology medications. The increased incidence of cancer worldwide can be attributed to a number of causes, including poor eating habits, inactivity, obesity, and rising alcohol and cigarette use. Cancer is mostly caused by genetics as well. Investments in healthcare via research and development are rising in many nations across the world. Every year, the US government spends a large amount on healthcare. Market Trends for Oncolytic Virus Immunotherapy In an effort to enhance the course and results of cancer treatment, researchers are always developing novel oncolytic viral immunotherapy clinical trials. Positive outcomes from a number of these clinical trials include higher survival rates and tumor shrinkage. Increased funding for clinical studies is one of the main elements supporting market expansion. To treat recurrent glioblastoma (rGBM), Mustang Bio, Inc. stated in April 2022 that it will launch a phase I clinical trial combining CAR T cells with oncolytic virus. The interim findings from two investigator-sponsored Phase I clinical studies evaluating MB-108 (the C134 oncolytic virus) and MB-101 (the targeted CAR T treatment from City of Hope) led to this start. Global Market for Oncolytic Virus Immunotherapy: Regional Outlook North America dominated the global industry in 2022. It is predicted that over the forecast period, the area would continue to hold its leading position. The expansion of market data in North America may be attributed to the existence of an advanced healthcare system that supports clinical trials, research partnerships between industry participants and academic institutions, and an innovative regulatory environment. Leading cancer treatment and research facility City of Hope announced in November 2021 the start of the first in-human clinical study to assess the use of an oncolytic virus that kills cancer in patients with advanced triple-negative breast cancer. The naturally occurring virus known as chimeric oncolytic orthopoxvirus is the source of the treatment known as CF33-hNIS-antiPDL1. Europe holds a significant market share in oncolytic virus immunotherapy, as seen by the active participation of Germany and the United Kingdom in several research initiatives and clinical studies aimed at promoting viral oncolysis. Global Oncolytic Virus Immunotherapy Market: Key Players Businesses involved in the global oncolytic viral immunotherapy market are collaborating and partnering to jointly study anticancer virus therapies. For instance, Virogin Biotech and the University of Texas MD Anderson Cancer Center established a strategic partnership in September 2022 with the aim of expediting the development of oncolytic viral immunotherapies and discovering predictive indicators of response. The following companies are well-known participants in the global oncolytic virus immunotherapy market: Merck & Co. Inc. (Viralytics Limited) Amgen Inc. TILT Biotherapeutics Key developments by the players in this market are: Siga Technologies declared in January 2022 that it has partnered with Bioarchitech on a pre-clinical project to develop viral immunotherapy for cancer. The research cooperation entails studying the latter's vaccinia-based immunotherapy platform, which uses tailored antibodies and several other proteins with oncolytic viral genome, in conjunction with the former's TPOXX (tecovirimat). A strategic agreement between Bionaut Labs and Candel Therapeutics, Inc. was announced in December 2021. The goal of the partnership is to explore the use of Bionaut Labs' remote-controlled microscale robots to accurately administer Candel Therapeutics' oncolytic viral immunotherapy medicines to brain tumors. Global Oncolytic Virus Immunotherapy Market Segmentation Type Have a Look at More Valuable Insights of Food and Beverages Breast Pumps Market : The global breast pumps market is estimated to flourish at a CAGR of 6.3% from 2022 to 2031. According to Transparency Market Research, market size of breast pumps is slated to surpass US$ 2.5 billion by the end of the aforementioned period of assessment. Insulin Market : According to Transparency Market Research, the global insulin market was worth USD 18.5 Bn in 2021. The market is predicted to reach USD 30 Bn by 2031, rising at a CAGR of 4.3% from 2022 to 2031. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact:

Bionaut Labs Frequently Asked Questions (FAQ)

  • When was Bionaut Labs founded?

    Bionaut Labs was founded in 2016.

  • Where is Bionaut Labs's headquarters?

    Bionaut Labs's headquarters is located at 3767 Overland Avenue, Los Angeles.

  • What is Bionaut Labs's latest funding round?

    Bionaut Labs's latest funding round is Series B - II.

  • How much did Bionaut Labs raise?

    Bionaut Labs raised a total of $63.63M.

  • Who are the investors of Bionaut Labs?

    Investors of Bionaut Labs include Upfront Ventures, Khosla Ventures, OurCrowd, Mayo Clinic, Gates Ventures and 15 more.

  • Who are Bionaut Labs's competitors?

    Competitors of Bionaut Labs include Affinia Therapeutics and 3 more.

  • What products does Bionaut Labs offer?

    Bionaut Labs's products include Bionaut - Dandy Walker Malformation and 1 more.

  • Who are Bionaut Labs's customers?

    Customers of Bionaut Labs include Candel Therapeutics.


Compare Bionaut Labs to Competitors

Activ Surgical

Activ Surgical is a digital surgery company that focuses on enhanced real-time visualization capabilities for surgeons. The company develops and strengthens software combining advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Its products include ActivSight, ActivEdge, ActivPerfusion, and ActivICG. The company was founded in 2017 and is based in Boston, Massachusetts.

Quantum Surgical Logo
Quantum Surgical

Quantum Surgical is a medical device company that focuses on healthcare innovation, particularly in the domain of medical robotics. The company's main offering is a robotic-assisted technology, which is designed to plan, target, deliver, and confirm tumor ablation, thereby enabling more patients to benefit from better-targeted and less invasive treatments. Quantum Surgical primarily serves the healthcare industry, with a specific focus on interventional oncology. It was founded in 2017 and is based in Montpellier, France.

CMR Surgical Logo
CMR Surgical

CMR Surgical operates as a surgical robotics company developing universal robotic systems for minimal access surgery. It aims to make minimal-access surgery universally accessible and affordable by expanding the range of procedures that can be performed robotically. CMR Surgical was formerly known as Cambridge Medical Robotics. It was founded in 2014 and is based in Cambridge, United Kingdom.

Dyno Therapeutics Logo
Dyno Therapeutics

Dyno Therapeutics develops a biotechnology platform. It applies artificial intelligence (AI) and quantitative high-throughput in vivo experiments to develop gene therapy. It enables medical researchers to access novel adeno-associated virus (AAV) vectors facilitating targeted delivery for new gene therapies. The company was founded in 2018 and is based in Watertown, Massachusetts.

Body Vision Medical

Body Vision Medical is a company that specializes in AI-driven, real-time, intraoperative imaging within the medical device industry. The company's main product, LungVision, is a platform that provides diagnostics and treatment for lung cancer, enhancing the way pulmonologists perform bronchoscopy and increasing the number of diagnostic procedures for early-stage lung cancer. The company primarily serves the healthcare industry, particularly in the field of pulmonology. It was founded in 2014 and is based in Ramat Hasharon, Israel.

Intuitive Surgical

Intuitive Surgical develops, manufactures and markets robotic surgical systems under the da Vinci Surgical brand.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.